Biotechnology

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Evolving Opportunities with AstraZeneca and Merck | Technavio

Friday, January 17, 2020 - 11:00pm

View the full release here: https://www.businesswire.com/news/home/20200117005292/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200117005292/en/
    Technavio has announced its latest market research report titled global PD-1 and PD-L1 inhibitors market 2019-2023.
  • The proven efficiency of PD-1 and PD-L1 inhibitors and strong pipeline are among factors anticipated to boost the growth of the market.
  • Request a free sample report
    Related Reports on Health Care include:
    MEK Inhibitors Market Global MEK Inhibitors Market by product (MEKINIST, COTELLIC, and MEKTOVI) and geography (Asia, Europe, North America, and ROW).
  • Phosphodiesterase (PDE) inhibitors Market Global Phosphodiesterase (PDE) inhibitors Market by application (oral, topical, and other RoA), and geography (Asia, Europe, North America, and ROW).

CytomX Therapeutics Announces New Employment Inducement Grants

Friday, January 17, 2020 - 9:10pm

The stock options were granted pursuant to the Companys 2019 Employment Inducement Incentive Plan, which was approved by the Companys board of directors in January 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Key Points: 
  • The stock options were granted pursuant to the Companys 2019 Employment Inducement Incentive Plan, which was approved by the Companys board of directors in January 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
  • CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.
  • Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while minimizing activity in healthy tissues.
  • PROBODY is a registered trademark of CytomX Therapeutics.

Generex Biotechnology Provides Investor Conference Call Details Tuesday January 21, 2020 at 9:30 AM

Friday, January 17, 2020 - 7:09pm

MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced Call-in details for the upcoming investor conference call on Tuesday January 21, 2020 at 9:30 AM Eastern time.

Key Points: 
  • MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced Call-in details for the upcoming investor conference call on Tuesday January 21, 2020 at 9:30 AM Eastern time.
  • The access information for the investor conference call is as follows:
    Direct Toll / International - 1-(203) 518-9865,
    As always, Generex President & Chief Executive Officer, Joseph Moscato welcomes questions from shareholders during the call.
  • Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies.
  • Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Real-Time Alerts Enable HHUNY to Improve Transitions for Incarcerated Individuals in New York State

Friday, January 17, 2020 - 7:00pm

Netsmart and Health Homes of Upstate New York (HHUNY) announced the expansion of their collaboration together, to include the incorporation of real-time justice system alerts designed to improve transitions for individuals entering and exiting correctional facilities.

Key Points: 
  • Netsmart and Health Homes of Upstate New York (HHUNY) announced the expansion of their collaboration together, to include the incorporation of real-time justice system alerts designed to improve transitions for individuals entering and exiting correctional facilities.
  • Time is of the essence when someone is going through a major life change, said HHUNY Executive Director Deborah Salgueiro.
  • Approximately 20 percent of jail inmates and 15 percent of state prison inmates have some form of serious mental illness.
  • The use of these alerts will allow the organizations to be more effective in supporting individuals during significant transitions.

MichBio Announces Creation of the “MichBio Diversity Network”

Friday, January 17, 2020 - 5:10pm

MichBio, the Michigan Bioscience Industry Association, is pleased to announce the creation of the MichBio Diversity Network focused on empowering the bio-workforce of the future.

Key Points: 
  • MichBio, the Michigan Bioscience Industry Association, is pleased to announce the creation of the MichBio Diversity Network focused on empowering the bio-workforce of the future.
  • In fact, according to the 2018 Why Diversity Matters report by McKinsey and Company, there is a direct link between the gender diversity and financial success.
  • Being a part of this group and the mission of the Diversity Network means to be connected with empowering women, says Kristin Tripp, Clinical Trial Associate at Vericel Corporation and Diversity Network committee member.
  • Look for MichBio Diversity Network events and activities throughout the year.

ISS Recommends Shareholders Vote FOR the Election of Harbert Discovery Fund Nominee to Enzo Biochem Board

Friday, January 17, 2020 - 4:56pm

ENZ has stated that it is a complicated business and shareholders may have a misunderstood view of the company.

Key Points: 
  • ENZ has stated that it is a complicated business and shareholders may have a misunderstood view of the company.
  • Although the board states that it has integrated shareholder feedback into its governance improvements, such feedback did not translate into changes until recently.
  • ISS also recognizes the additive experience of Peter Clemens:
    Earlier this week, proxy advisory firm, Glass, Lewis & Co. (Glass Lewis) recommended shareholders vote for both HDF nominees.
  • Important Information about Participants in a Proxy Solicitation:
    Harbert Discovery Fund, LP (Harbert Discovery), Harbert Discovery Fund GP, LLC (Harbert Discovery GP), Harbert Discovery Co-Investment Fund I, LP (Harbert Discovery Co-Investment and together with Harbert Discovery, the Discovery Funds), Harbert Discovery Co-Investment Fund I GP, LLC (Harbert Discovery Co-Investment GP), Harbert Fund Advisors, Inc. (HFA), Harbert Management Corporation (HMC), Jack Bryant (Mr. Bryant), Raymond Harbert (Mr. Harbert) and Kenan Lucas (Mr. Lucas and together with Harbert Discovery, Harbert Discovery GP, Harbert Discovery Co-Investment, Harbert Discovery Co-Investment GP, HFA, HMC and Messrs. Bryant and Harbert, the Harbert Discovery Parties) (collectively, the Participants) have filed with the Securities and Exchange Commission (the SEC) a definitive proxy statement and accompanying form of proxy to be used in connection with the solicitation of proxies from the shareholders of Enzo Biochem, Inc. (the Company) in connection with the annual meeting of shareholders of the Company (the Annual Meeting).

ERS Genomics Provides Comment on EPO Technical Board of Appeal Decision Upholding the Revocation of Broad Institute CRISPR Patent

Friday, January 17, 2020 - 4:50pm

EP2771468 is viewed as the Broad Institutes foundational CRISPR-Cas9 patent in Europe.

Key Points: 
  • EP2771468 is viewed as the Broad Institutes foundational CRISPR-Cas9 patent in Europe.
  • The Broad Institute appealed the Opposition Divisions decision, which the Board affirmed yesterday.
  • Thus, all claims of the Broad Institutes patent remain fully revoked with no option left to overturn this decision.
  • The Broad Institute obtained nine other patents that all suffer from the very same defect that resulted in the revocation of this first patent.

6th Perinatal Stem Cell Society Congress | Salt Lake City, United States - March 4th-6th, 2020

Friday, January 17, 2020 - 3:45pm

DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "6th Perinatal Stem Cell Society Congress" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "6th Perinatal Stem Cell Society Congress" conference has been added to ResearchAndMarkets.com's offering.
  • The International Perinatal Stem Cell Society, Inc. is a non-profit organization founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders.
  • Networking opportunities to cultivate relationships with relevant and engaged colleagues and organizations.
  • A unique opportunity to learn from the leading clinicians utilizing cellular therapies in their practices.

The global tumor (cancer) profiling market at a CAGR of over 10% during the forecast period

Friday, January 17, 2020 - 3:15pm

Global Tumor (Cancer) Profiling Market: About this market

Key Points: 
  • Global Tumor (Cancer) Profiling Market: About this market
    This tumor (cancer) profiling market analysis considers sales from immunoassays, next-generation sequencing, polymerase chain reaction, and in-situ hybridization technologies.
  • Also, our global tumor (cancer) profiling market report looks at factors such as increasing incidences of cancer, low cost of genetic sequencing, and increasing awareness about tumor profiling.
  • Global Tumor (Cancer) Profiling Market: Overview
    Various government and private organizations and companies are creating awareness about the significance of tumor profiling, its diagnosis and personalized treatment of cancer.
  • Thus, increasing awareness about tumor profiling will lead to the expansion of the global tumor (cancer) profiling market at a CAGR of over 10% during the forecast period.

Alpha Holdings Comments on OncoSec’s Failure to Consider Superior Financing Proposal

Friday, January 17, 2020 - 2:30pm

Alpha Holdings stated: It is outrageous that OncoSecs Board will not even discuss Alphas superior proposal, and their knee-jerk rejection of $9.3 million in additional value confirms our view that the Company needs new leadership.

Key Points: 
  • Alpha Holdings stated: It is outrageous that OncoSecs Board will not even discuss Alphas superior proposal, and their knee-jerk rejection of $9.3 million in additional value confirms our view that the Company needs new leadership.
  • If its proposal were accepted, Alpha would continue to be OncoSecs largest stockholder.
  • It is completely illogical to believe Alpha would invest $25 million only to allow OncoSec to run out of money.
  • 1 China Grand refers collectively to China Grand Pharmaceuticals and Healthcare Holdings (CGP) and Sirtex Medical US Holdings, Inc. (Sirtex), an affiliate of GCP.